Pazdur R - Search Results

1

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.

Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R. Brave M, et al. Among authors: pazdur r. Oncology. 2010;78(3-4):282-8. doi: 10.1159/000315736. Epub 2010 Jun 8. Oncology. 2010. PMID: 20530974

2

Oncology drug development: United States Food and Drug Administration perspective.

Hirschfeld S, Pazdur R. Hirschfeld S, et al. Among authors: pazdur r. Crit Rev Oncol Hematol. 2002 May;42(2):137-43. doi: 10.1016/s1040-8428(02)00008-2. Crit Rev Oncol Hematol. 2002. PMID: 12007971 Review.

3

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.

Hirschfeld S, Ho PT, Smith M, Pazdur R. Hirschfeld S, et al. Among authors: pazdur r. J Clin Oncol. 2003 Mar 15;21(6):1066-73. doi: 10.1200/JCO.2003.11.138. Epub 2003 Feb 7. J Clin Oncol. 2003. PMID: 12637472 Review.

4

End points and United States Food and Drug Administration approval of oncology drugs.

Johnson JR, Williams G, Pazdur R. Johnson JR, et al. Among authors: pazdur r. J Clin Oncol. 2003 Apr 1;21(7):1404-11. doi: 10.1200/JCO.2003.08.072. J Clin Oncol. 2003. PMID: 12663734

5

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Ibrahim A, et al. Among authors: pazdur r. Clin Cancer Res. 2003 Jul;9(7):2394-9. Clin Cancer Res. 2003. PMID: 12855610 Clinical Trial.

6

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Kane RC, Bross PF, Farrell AT, Pazdur R. Kane RC, et al. Among authors: pazdur r. Oncologist. 2003;8(6):508-13. doi: 10.1634/theoncologist.8-6-508. Oncologist. 2003. PMID: 14657528 Free article. Review.

7

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, Leighton J, Liang CY, Lostritto RT, McGuinn WD, Morse DE, Rahman A, Rosario LA, Verbois SL, Williams G, Wang YC, Pazdur R. Bross PF, et al. Among authors: pazdur r. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3954-64. doi: 10.1158/1078-0432.CCR-03-0781. Clin Cancer Res. 2004. PMID: 15217925 Clinical Trial. No abstract available.

8

Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

Talarico L, Chen G, Pazdur R. Talarico L, et al. Among authors: pazdur r. J Clin Oncol. 2004 Nov 15;22(22):4626-31. doi: 10.1200/JCO.2004.02.175. J Clin Oncol. 2004. PMID: 15542812

9

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R. Hazarika M, et al. Among authors: pazdur r. Clin Cancer Res. 2005 Feb 1;11(3):982-92. Clin Cancer Res. 2005. PMID: 15709163

10

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. Kaminskas E, et al. Among authors: pazdur r. Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176. Oncologist. 2005. PMID: 15793220 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

603 results

Search Page

Filters